Skip to main navigation

Skip to content

Search for:

About
Technology
Pipeline
Products
- XIPERE®
Investors

Investor Menu

IR Overview
News
Events and Presentations
Governance
SEC Filings
Financial Info
Resources

News

Year

Nov 22 2022

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

Nov 10 2022

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

Nov 9 2022

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 9 2022

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Nov 8 2022

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

Nov 2 2022

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

Oct 4 2022

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

Sep 27 2022

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Aug 25 2022

Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

Aug 9 2022

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Current page 1
Page 2
Page 3
Next page
Last page

Email Alerts
Print Page
RSS Feeds
IR Contact

Request Email Alerts

(678) 270-3631
info@clearsidebio.com
CONTACT US

ABOUT US
MANAGEMENT
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
PRIVACY POLICY

SCIENCE
SUPRACHOROIDAL SPACE
SCS MICROINJECTOR®
PUBLICATIONS & PRESENTATIONS
Intellectual Property

PRODUCTS
XIPERE™

PIPELINE
CLS-AX
INTEGRIN INHIBITOR
GENE THERAPY
COLLABORATIONS

INVESTORS
IR OVERVIEW
NEWS
EVENTS & PRESENTATIONS
GOVERNANCE
SEC FILINGS
FINANCIAL INFO
RESOURCES

Copyright 2022 © Clearside Biomedical | Website Design and Development by Emma Tang Designs